Skip to main content
SpringerLink
Log in

Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2012;40:486–95. doi:10.1007/s00259-012-2298-2.

    Article  PubMed  Google Scholar 

  2. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. Erratum to: PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013. doi:10.1007/s00259-013-2378-y.

    Google Scholar 

  3. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2013;53:1883–91.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany

    A. Afshar-Oromieh, A. Malcher, F. L. Giesel, C. Kratochwil, S. Haufe, U. Haberkorn & C. M. Zechmann

  2. Department of Radiopharmaceutical Chemistry, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany

    M. Eder & M. Eisenhut

  3. National Center for Tumor Diseases (NCT)/DKFZ, Im Neuenheimer Feld 581, 69120, Heidelberg, Germany

    H. G. Linhart

  4. Department of Urology, University Hospital of Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany

    B. A. Hadaschik

  5. Department of Biostatistics, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany

    T. Holland-Letz

  6. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre, Heidelberg, Germany

    U. Haberkorn

Authors
  1. A. Afshar-Oromieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Malcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Eder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Eisenhut
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. G. Linhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. A. Hadaschik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Holland-Letz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. L. Giesel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Kratochwil
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Haufe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. U. Haberkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. M. Zechmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Afshar-Oromieh.

Additional information

This reply refers to the comment available at doi:10.1007/s00259-013-2385-z.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Afshar-Oromieh, A., Malcher, A., Eder, M. et al. Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40, 971–972 (2013). https://doi.org/10.1007/s00259-013-2386-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2386-y

Keywords

Search

Navigation